Events
Calendar of Events
|
M
Monday
|
T
Tuesday
|
W
Wednesday
|
T
Thursday
|
F
Friday
|
S
Saturday
|
S
Sunday
|
|---|---|---|---|---|---|---|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
3 events,
Learn more about how Type 2 inflammation contributes to the clinical manifestations of atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU), and bullous pemphigoid (BP); which cytokines play key roles in driving this activity; and a treatment option that may help appropriate patients.
Learn more about the diagnosis and assessment of chronic spontaneous urticaria (CSU), including its clinical manifestations, diagnostic evaluation, assessment scales, and a treatment option for appropriate patients with CSU.
Explore how IL-4 and IL-13 act as key mediators in the underlying pathophysiology of atopic dermatitis (AD), including their contribution to chronic inflammation, itch signaling, immune dysregulation, and impairment of skin barrier integity; and a treatment option that may help appropriate patients by selectively targeting these cytokine pathways. |
2 events,
Learn more about a treatment option that may help appropriate patients with prurigo nodularis (PN), and chronic spontaneous urticaria (CSU).
Learn more about a treatment option that may help appropriate patients with bullous pemphigoid (BP). |
3 events,
Learn more about a treatment option that may help appropriate patients with atopic dermatitis (AD), and chronic spontaneous urticaria (CSU).
Learn more about how to diagnose and assess uncontrolled moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients.
Learn more about how Type 2 inflammation contributes to the clinical manifestations of atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU), and bullous pemphigoid (BP); which cytokines play key roles in driving this activity; and a treatment option that may help appropriate patients. |
0 events,
|
0 events,
|
0 events,
|
3 events,
Learn more about how Type 2 inflammation contributes to the clinical manifestations of atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU), and bullous pemphigoid (BP); which cytokines play key roles in driving this activity; and a treatment option that may help appropriate patients.
Learn more about how Type 2 inflammation contributes to the clinical manifestations of atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU), and bullous pemphigoid (BP); which cytokines play key roles in driving this activity; and a treatment option that may help appropriate patients.
Learn more about the clinical presentation and diagnostic workup of prurigo nodularis (PN) and a treatment option that may help appropriate patients. |
2 events,
Learn more about a treatment option that may help appropriate patients with prurigo nodularis (PN).
Learn more about how to diagnose and assess uncontrolled moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients. |
3 events,
A Treatment Option for Appropriate Patients With Chronic Spontaneous Urticaria
by Carsten Hamann, MD
A Treatment Option for Appropriate Patients With Chronic Spontaneous Urticaria
by Carsten Hamann, MD Learn more about a treatment option that may help appropriate patients with chronic spontaneous urticaria (CSU).
Learn more about a treatment option that may help appropriate patients with atopic dermatitis (AD) and prurigo nodularis (PN).
Learn more about the diagnosis and assessment of bullous pemphigoid (BP), including clinical manifestations, key laboratory investigations for diagnostic evaluation, consensus-based recommendations, and a treatment option for appropriate patients with BP. |
2 events,
Learn more about a treatment option that may help appropriate patients with atopic dermatitis (AD).
Learn more about how Type 2 inflammation contributes to the clinical manifestations of atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU), and bullous pemphigoid (BP); which cytokines play key roles in driving this activity; and a treatment option that may help appropriate patients. |
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|